Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / MRK - Merck and Surface Oncology partner for Keytruda combination in cancer trial

MRK - Merck and Surface Oncology partner for Keytruda combination in cancer trial

Merck & Company Inc.
Surface Oncology (SURF) has announced a collaboration with Merck (MRK) to evaluate Surface’s investigational antibody therapy SRF388 in combination with Merck’s anti-PD-1 therapy Keytruda (pembrolizumab).The therapeutic combination will be part of the first-in-human Phase 1 study of SRF388 that will evaluate its effect in patients with solid tumors, with a focus on those with liver cancer and kidney cancer.  In April 2020, Surface oncology announced the initiation of Phase 1 clinical trial to evaluate the escalating doses of interleukin-27 (IL-27) inhibitor SRF388 in patients with advanced solid tumors.

For further details see:

Merck and Surface Oncology partner for Keytruda combination in cancer trial
Stock Information
Company Name: Merck & Company Inc.
Stock Symbol: MRK
Market: NYSE
Website: merck.com
Menu
MRK MRK Quote MRK Short MRK News MRK Articles MRK Message Board
Get MRK Alerts

News, Short Squeeze, Breakout and More Instantly...